Inclusion Criteria:

1. Signed informed consent form

2. Age 18-75 years;

3. Histologically or cytologically confirmed gastric cancer;

4. Advanced or recurrent, metastatic disease;

5. Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1;

6. Life expectancy of at least 12 weeks;

7. At least have one measurable disease(according to RECIST, Response Evaluation
Criteria in Solid Tumors )

8. Subjects who have received one prior regimen for gastric carcinoma and developed
disease progression or recurrence within 6 months after the end of systemic adjuvant
treatment. The regimen must have contained fluorouracil(e.g. 5-FU,capecitabine)
and/or cisplatin;

9. Haematopoietic status:

- Absolute neutrophil count > 1.5 x 109/L,

- Platelet count > 90 x 109/L,

- Hemoglobin at least 9 g/dl,

10. Hepatic status:

- Bilirubin ≤ 1.5 x upper limit of normal (ULN),

- AST and ALT ≤ 2.5 times ULN(no liver metastasis), ≤5 times ULN(with liver
metastasis)

11. Renal status:

- Creatinine ≤1.5 times ULN or calculated creatinine clearance, using the
Cockcroft-Gault formula, ≥40 mL/min;

12. Able to swallow and retain oral medication；without malabsorption syndrome, or disease
significantly affecting gastrointestinal function, such as ulcerative colitis and
Crohn's disease;

13. Cardiovascular: Baseline LVEF 50% measured by echocardiography (ECHO) ;

14. Negative serum pregnancy test (For women of childbearing potential);Fertile patients
must use effective contraception.

Exclusion Criteria:

1. Received any prior treatment including taxane or S-1;

2. Concurrent systemic anti-cancer therapy (immunotherapy, biologic therapy, hormone
therapy, etc ); received treatment with an investigational agent or participation in
another therapeutic clinical trial within 4 weeks;

3. Unresolved or unstable, serious toxicity from prior cancer treatment (any toxicities
greater than grade 2; peripheral neuropathy of grade 2 or greater

4. Symptomatic brain metastasis;

5. Known history of uncontrolled or symptomatic angina, clinically significant
arrhythmias, congestive heart failure, uncontrolled hypertension (≥ 180/110),
unstable diabetes mellitus, dyspnea at rest, or chronic therapy with oxygen;

6. History of other malignancy. However, subjects with a past or current history of
completely resected basal and squamous cell carcinoma of the skin or successfully
treated in situ carcinoma of the cervix are eligible

7. Dementia, altered mental status, or any psychiatric condition that would prevent the
understanding or rendering of ICF;

8. Active or uncontrolled infection;

9. Concurrent treatment with an investigational agent or participation in another
therapeutic clinical trial;

10. Pregnant or lactating women.